©2022 Stanford Medicine
Therapy for Pediatric Hodgkin Lymphoma
Trial ID: NCT00145600
With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.
Risk-Adapted Therapy for Pediatric Hodgkin's Disease
- Eligible patients must have histologically confirmed previously untreated Hodgkin's
disease (Patients receiving limited emergent RT or steroid therapy because of
cardiopulmonary decompensation or spinal cord compression will be eligible for
- Patients must be 21 years of age or younger
- Ann Arbor stages IIB-IV
- No prior treatment.
- No pregnant or lactating women.
- Signed informed consent
- If re-evaluation of a patient's disease shows favorable risk features or intermediate
risk features, the patient will be removed from the HOD99 study and consented to the
respective HOD08 or HOD05 study.
Inclusion: treatment of favorable risk features:
- Ann Arbor IA or IIA with:
1. Non-bulky mediastinal disease (<33% mediastinal to thoracic ratio on chest x ray)
2. Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions
(s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy
(mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)
Inclusion: unfavorable risk features:
- Stage must be classified as one of the following:
1. Ann Arbor stage IIB, IIIB, or any IV
drug: 12 Week Stanford V Chemotherapy
drug: 4 cycles of VAMP chemotherapy
drug: 2 alternating cycles of VAMP/COP chemotherapy
drug: 3 alternating cycles of VAMP/COP chemotherapy
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs